Imperial College London
Alternate

Professor Neil Poulter

Faculty of Medicine, School of Public Health

Professor of Preventive Cardiovascular Medicine.
 
 
 
//

Contact

 

+44 (0)20 7594 3446n.poulter

 
 
//

Assistant

 

Mrs Ranjit Rayat +44 (0)20 7594 3445

 
//

Location

 

55Stadium HouseWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Vilsbøll:2019:10.1111/dom.13675,
author = {Vilsbøll, T and Blevins, TC and Jodar, E and Poulter, N and Tentolouris, N and Ross, Agner BF and Lehmann, L and Leiter, LA},
doi = {10.1111/dom.13675},
journal = {Diabetes, Obesity and Metabolism},
pages = {1506--1512},
title = {Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin},
url = {http://dx.doi.org/10.1111/dom.13675},
volume = {21},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - In this post hoc analysis we investigated the effects of insulin degludec/liraglutide fixed-ratio combination (IDegLira) versus comparators on cardiovascular (CV) risk markers in participants in the DUAL II (vs. insulin degludec), DUAL V (vs. insulin glargine 100 units/mL) and DUAL VII (vs. basal-bolus therapy) trials, grouped by sex, age (<65 years, ≥65 years) and diabetes duration (<10 years, ≥10 years). Treatment contrasts were in favour of IDegLira in many subgroups for changes from baseline in glycated haemoblogin (DUAL II, DUAL V), body weight (all three trials), systolic blood pressure (BP; all three trials), HDL cholesterol (DUAL VII) and LDL cholesterol (DUAL II, DUAL V). Higher heart rates were seen with IDegLira versus comparators (all three trials) plus significantly higher diastolic BP in men (DUAL V). Differences in treatment effect were seen between sexes in waist circumference (DUAL II), systolic BP (DUAL II, DUAL V) and triglycerides (DUAL VII), and between diabetes durations in LDL cholesterol (DUAL V). In conclusion, IDegLira is associated with a general improvement in CV risk markers compared with basal insulin or basal-bolus therapy after 26 weeks of treatment.
AU  - Vilsbøll,T
AU  - Blevins,TC
AU  - Jodar,E
AU  - Poulter,N
AU  - Tentolouris,N
AU  - Ross,Agner BF
AU  - Lehmann,L
AU  - Leiter,LA
DO  - 10.1111/dom.13675
EP  - 1512
PY  - 2019///
SN  - 1462-8902
SP  - 1506
TI  - Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin
T2  - Diabetes, Obesity and Metabolism
UR  - http://dx.doi.org/10.1111/dom.13675
UR  - https://www.ncbi.nlm.nih.gov/pubmed/30785655
UR  - http://hdl.handle.net/10044/1/69441
VL  - 21
ER  -
Download